Castle Biosciences, Inc. (Nasdaq: CSTL) has recently shared new performance data from a multi-center, independent cohort that confirms the independent risk-stratification of DecisionDx®-SCC (the Company’s 40-gene expression profile (GEP) test). The data shows how DecisionDx-SCC can significantly improve metastatic risk predictions by complementing current staging systems (AJCC81 and BWH2).
Moreover, DecisionDx-SCC was found to independently and significantly stratify a novel cohort according to patients’ biologic metastatic risk (p<0.0001). This new data further strengthens the value of DecisionDx-SCC in improving patient care.
At the 2023 American Academy of Dermatology (AAD) Annual Meeting, Ashley Wysong, M.D., M.S., F.A.A.D., William W. Bruce, M.D. Distinguished Chair of Dermatology and Founding Chair of the Department of Dermatology at the University of Nebraska Medical Center, will be delivering a late-breaking oral presentation to share the findings of an exciting new study. Don’t miss this chance to learn about the groundbreaking results of this research!
The death toll from cutaneous squamous cell carcinoma (cSCC) is now projected to overtake that of melanoma, making it critical to develop tools that provide independent information about patients’ risk of metastasis. A new study has shown that gene expression profiling can significantly improve predictions of metastatic risk above and beyond the traditional staging systems. The development of the 40-GEP test will be an invaluable aid in providing risk-adjusted care decisions for cSCC patients at high risk of metastasis.
This study demonstrated the outstanding performance of the DecisionDx-SCC test in a novel, independent performance cohort of 534 patients with primary cSCC and one or more risk factors from 45 contributing centers. DecisionDx-SCC was able to accurately classify risk for metastasis in cSCC patients with one or more risk factors (p<0.0001).
Multivariate models showed that the metastatic risk prediction of AJCC8 and BWH staging systems were significantly improved when DecisionDx-SCC test results were included, thereby improving risk predictions based on staging alone and aiding in more informed patient management decisions.
About DecisionDx®-SCC
DecisionDx-SCC is an innovative 40-gene expression profile test that helps physicians accurately assess an individual’s risk of cutaneous squamous cell carcinoma metastasis. With the help of this test, patients are classified into a Class 1 (low risk), Class 2A (moderate risk) or Class 2B (high risk) category, allowing doctors to tailor their treatment plans accordingly. By utilizing an individual’s tumor biology, DecisionDx-SCC provides a more precise and personalized way to manage risk.
DecisionDx-SCC has been scientifically proven to be an effective predictor of metastatic risk, with peer-reviewed publications demonstrating that incorporating DecisionDx-SCC into existing prognostic methods can significantly improve clinical decision-making for staging and management of patients. This groundbreaking advancement in predicting cancer progression has the potential to transform the way clinicians approach patient care.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is revolutionizing healthcare through its cutting-edge diagnostics tests that empower clinicians to make the best decisions for their patients. We put people first – patients, clinicians, employees and investors – as we strive to transform disease management and improve the lives of those affected.
At Castle, we are dedicated to developing innovative solutions for medical conditions that require urgent attention. Our cutting-edge portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions.
We are also actively researching and developing tests for other diseases, including a test to predict systemic therapy responses for patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. Join us in our mission to provide the best care possible to those in need.